Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (NASDAQ: LUCD) is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. News about Lucid centers on its efforts to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, using its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
On this page, readers can follow Lucid’s announcements on business updates, financial results, capital-raising activities, and clinical data related to EsoGuard and EsoCheck. Company press releases have highlighted quarterly financial results, the number of EsoGuard tests processed, and revenues associated with those tests, reflecting the commercial adoption of its esophageal precancer detection tools.
Lucid’s news flow also includes developments in reimbursement and coverage, such as Medicare Local Coverage Determination (LCD) processes and Contractor Advisory Committee (CAC) meetings where medical experts have discussed coverage for EsoGuard. The company issues updates on these milestones because they are important for expanding patient access and insurance coverage for its tests.
In addition, Lucid regularly announces participation in investor and industry conferences, business update webcasts, and leadership appointments related to market access and government affairs. Clinical and real-world data updates, including large analyses of EsoGuard and EsoCheck performance in routine practice, are another key component of its news, providing insight into safety, tolerability, technical success, and use in at-risk GERD populations.
Investors and observers can use this news page to track Lucid’s progress as a commercial-stage diagnostics company focused on early detection of esophageal precancer, along with its financial disclosures and strategic communications.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has priced its initial public offering (IPO) of 5,000,000 shares at $14.00 per share, aiming for gross proceeds of $70 million. The offering will close around October 18, 2021. Additionally, underwriters have a 30-day option to purchase 750,000 extra shares. The stock is set to begin trading on Nasdaq on October 14, 2021. Lucid focuses on cancer prevention through its EsoGuard® test for at-risk GERD patients, which is a breakthrough device under FDA review.
Lucid Diagnostics Inc. has announced the pricing of its initial public offering (IPO) of 5 million shares at $14.00 per share, aiming to raise $70 million before expenses. The IPO will launch on October 14, 2021, and is expected to close on or around October 18, 2021. The underwriters have a 30-day option to purchase an additional 750,000 shares. Lucid, a subsidiary of PAVmed Inc., focuses on cancer prevention, particularly for patients suffering from gastroesophageal disease at risk of esophageal cancer, using its EsoGuard® diagnostic test.